Annual Results Presentation 23 rd May 2016 Ian Jefferson - CFO
|
|
- Evelyn Hubbard
- 6 years ago
- Views:
Transcription
1 Annual Results Presentation 23 rd May 2016 Ian Jefferson - CFO 1
2 Financial Overview Selected Highlights Income statement Jan Jan 2015 Revenue Cost of sales (154) (32) Gross Margin Overheads (10,904) (8,437) Operating Profit (10,242) (8,369) Finance income Loss before taxation (10,029) (8,201) Taxation Loss after tax (9,502) (7,581) Attributable to: Equity holders of parent (9,410) (7,581) Non-controlling interests (92) - Balance sheet Jan Jan 2015 Property, plant & equipment Inventory Trade & other receivables 2,325 1,947 Cash & cash equivalent 19,907 10,257 Total net assets 23,197 12,673 Trade & other payables (1,958) (1,095) Net Assets 21,239 11,578 Highlights Strong revenue growth from DermaPure in first full year of sales since launch High margins at 81% (2015: 68%) Overheads increase driven by cost of US sales & marketing organisation and clinical trial costs for orthopaedic products The Group continues to benefit from R&D tax credits Loss after tax of 9.5m in line with expectations Healthy cash balance of 19.9m. TISSUE REGENIX GROUP P L C 2
3 Financial Overview Segmental Overview SEGMENTAL 000 WOUND CARE ORTHOPAEDICS CARDIAC CENTRAL TOTAL Total segment Inter-segment (76) (76) - - (152) - Revenue Cost of sales (154) (32) (154) (32) Gross Margin Development (1,108) (1,029) (2,279) (2,032) (289) (235) - - (3,676) (3,296) Sales & marketing (3,672) (1,766) (3,672) (1,766) Operations (158) (48) (103) (22) (63) (15) (3,232) (3,290) (3,556) (3,375) Operating Profit (4,284) (2,803) (2,382) (2,054) (352) (250) (3,224) (3,262) (10,242) (8,369) TISSUE REGENIX GROUP P L C 3
4 F i n a n c i a l O v e r v i e w S e g m e n t a l O v e r v i e w Wound Care SEGMENTAL 000 WOUND CARE ORTHOPAEDICS CARDIAC CENTRAL TOTAL Total segment Inter-segment (76) (76) - - (152) - Revenue Cost of sales (154) (32) (154) (32) Gross Margin Development (1,108) (1,029) (2,279) (2,032) (289) (235) - - (3,676) (3,296) Sales & marketing (3,672) (1,766) (3,672) (1,766) Operations (158) (48) (103) (22) (63) (15) (3,232) (3,290) (3,556) (3,375) Operating Profit (4,284) (2,803) (2,382) (2,054) (352) (250) (3,224) (3,262) (10,242) (8,369) Revenue derived from DermaPure sales ($1.2m) in the US. Gross margins 81% c.f. 56% (underlying 86% c.f. 82%). Development expenditure relates to DermaPure clinical trial and 510k process for SurgiPure XD Sales & marketing costs include commission of 303k (2015: 21k), 37.5% (2015: 29.2%) of revenue TISSUE REGENIX GROUP P L C 4
5 F i n a n c i a l O v e r v i e w S e g m e n t a l O v e r v i e w Orthopaedics SEGMENTAL 000 WOUND CARE ORTHOPAEDICS CARDIAC CENTRAL TOTAL Total segment Inter-segment (76) (76) - - (152) - Revenue Cost of sales (154) (32) (154) (32) Gross Margin Development (1,108) (1,029) (2,279) (2,032) (289) (235) - - (3,676) (3,296) Sales & marketing (3,672) (1,766) (3,672) (1,766) Operations (158) (48) (103) (22) (63) (15) (3,232) (3,290) (3,556) (3,375) Operating Profit (4,284) (2,803) (2,382) (2,054) (352) (250) (3,224) (3,262) (10,242) (8,369) Clinical trial started on both OrthoPure XM and OrthoPure XT Expenditure expected to increase again in current period as patient numbers grow TISSUE REGENIX GROUP P L C 5
6 F i n a n c i a l O v e r v i e w S e g m e n t a l O v e r v i e w Cardiac SEGMENTAL 000 WOUND CARE ORTHOPAEDICS CARDIAC CENTRAL TOTAL Total segment Inter-segment (76) (76) - - (152) - Revenue Cost of sales (154) (32) (154) (32) Gross Margin Development (1,108) (1,029) (2,279) (2,032) (289) (235) - - (3,676) (3,296) Sales & marketing (3,672) (1,766) (3,672) (1,766) Operations (158) (48) (103) (22) (63) (15) (3,232) (3,290) (3,556) (3,375) Operating Profit (4,284) (2,803) (2,382) (2,054) (352) (250) (3,224) (3,262) (10,242) (8,369) Joint Venture set up with tissue bank in Germany First licence for heart valve technology TISSUE REGENIX GROUP P L C 6
7 F i n a n c i a l O v e r v i e w S e g m e n t a l O v e r v i e w Central SEGMENTAL 000 WOUND CARE ORTHOPAEDICS CARDIAC CENTRAL TOTAL Total segment Inter-segment (76) (76) - - (152) - Revenue Cost of sales (154) (32) (154) (32) Gross Margin Development (1,108) (1,029) (2,279) (2,032) (289) (235) - - (3,676) (3,296) Sales & marketing (3,672) (1,766) (3,672) (1,766) Operations (158) (48) (103) (22) (63) (15) (3,232) (3,290) (3,556) (3,375) Operating Profit (4,284) (2,803) (2,382) (2,054) (352) (250) (3,224) (3,262) (10,242) (8,369) Costs held flat and expected to remain so for current period Costs include Group costs and standard operation overheads TISSUE REGENIX GROUP P L C 7
8 Financial Overview HIGHLIGHTS Results in line with expectations and significant progress across all operating division Transition from development stage to revenue generation in wound care successfully executed Both orthopaedic products in clinical trials Joint Venture and licencing deal with tissue bank in Germany for cardiac technology GUIDANCE (next 12 months) DermaPure will be the key revenue generator, $2.5m - $4.5m Cost base increases, as the business continues to progress as planned, for: - Wound care sales & marketing to support DermaPure revenue growth -Orthopaedic development as porcine products move through clinical trials to CE marking Note next reporting period only 11 months to Dec16 TISSUE REGENIX GROUP P L C
9 Corporate Highlights Antony Odell - CEO 9
10 Corporate Highlights Commercial Progress $1m revenue mark achieved with DermaPure FDA approval for SurgiPure GBM-V ggmbh joint venture Development Progress 20 patients recruited into OrthoPure XM (porcine meniscus) EU regulatory clinical trial OrthoPure XT (porcine tendon) EU regulatory clinical trial started Operational Progress Relocation to Leeds facility TISSUE REGENIX GROUP P L C 10
11 $1.2m revenue FY 16 74% coverage of Medicare beneficiaries Progress on private/managed Medicare Acute (hospital) sales Ortho, Trauma, Maxillo-facial Chronic (wound center) sales DFU, VLU, Pressure ulcers Strong clinical support for product 12 KOL s 14 clinical abstracts TISSUE REGENIX GROUP P L C 11
12 Product positioning highlights differentiated mechanism of action TISSUE REGENIX GROUP P L C 12
13 510K FDA Market Approval Important as first time FDA has reviewed full dcell process Launch H Seeking to appoint a national distributor Focus on complex hernias Key competitor: Acelity [Straticce ] TISSUE REGENIX GROUP P L C 13
14 GBM-V ggmbh Joint Venture Enables deployment of dcell human tissue technology in EU Initial licences for CardioPure HAV & HPV (Human Aortic/Pulmonary Valves) & DermaPure Annual technology access fee per application 100k Processing fee per tissue (valve/cm 2 etc.) Initial revenues from cryo-tissues (cornea, heart valves) Regulatory approvals H216 Regulatory submissions for dcell in progress Regulatory approvals mid 2017 Donor base expanding to plan TISSUE REGENIX GROUP P L C 14
15 Development Progress -Regulatory Pathways 20 patients recruited into (Xenograft Meniscus) EU regulatory clinical trial Data collection & review in progress (Xenograft Tendon) EU regulatory clinical trial started 60% recruited TISSUE REGENIX GROUP P L C 15
16 Operational Progress Relocation to Leeds facility Previously FDA approved facility Annual costs lower than York Biocentre Manufacturing lines in development for SurgiPure XD & OrthoPure porcine products Human tissue processed by partners (US, Germany) Manufacturing efficiency focus on COG/streamlining processes TISSUE REGENIX GROUP P L C 16
17 Looking Forward 12 months DermaPure commercial traction on remaining MACS (2) & commercial payors DermaPure (thicker Dermis) launch for tissue replacement, dental & other applications Regulatory updates on OrthoPure products (XM & XT) Launch of SurgiPure XD for complex hernias in US GBM-V regulatory approvals for cryo-tissues 17 Progress update on dcell submissions to PEI US orthopaedic updates (human & xeno) TISSUE REGENIX GROUP P L C
18 TISSUE REGENIX GROUP P L C 18
19 Decellularized Human Heart Valves and Pericardial Patches Outcomes at 10 Years and Future Perspectives Francisco Diniz Affonso da Costa Head Cardiovascular Surgery PUCPR - Brazil
20 Conventional Heart Valve Substitutes & frequent complications Mechanical Valves Biological Valves Human Valves Allografts
21 Why to use a Homograft Physiologic hemodynamic performance Almost null incidence of thromboembolism Does not require anticoagulation Very resistant to infection Associated with better patient survival Better durability compared to conventional bioprosthesis Limited supply Implantation techniques more complex
22 Heart Valve Allografts Main Indications 1. Correction of Complex Congenital Defects 2. RVOT Reconstruction During the Ross Operation 3. AVR for Bacterial Endocarditis 4. AVR in patients with Small Ao Roots 5. AVR in Younger Patients with contraindications for anticoagulation 6. AVR in Pregnant Women
23 Decellularized Heart Valve Allografts SDS Decellularization Technique Fresh Allografts, no cryopreservation Storage at 4º C for up to 3 months
24 Decellularized Heart Valves Brazilian Experience ( ) Number of implants = 1502 cases
25 Cryopreserved Pulmonary Valve Allografts Mechanisms of Allograft Stenosis Early (2 years) Late (> 5 years) Proximal Anastomosis Conduit Retraction Distal Anastomosis Calcification Degeneration
26 Fresh Decellularized Pulmonary Valve Allografts For RVOT Reconstruction During The Ross Operation Clinical Outcomes at 10Years Fresh dcell x Cryopreserved Allografts This study - n = 374 (includes all consecutive patients operated at the author s official institution who received either a cryopreserved or a fresh dcell allograft for RVOT reconstruction) Francisco D. Costa 1, Eduardo Balbi, Filho 2, Rafael Torres 2, Daniele Colatusso 1, Claudinei Colatusso 1, Allysson Calixto 2, Marise Costa 1. 1 Santa Casa de Curitiba PUCPR, Curitiba, Brazil, 2 Instituto de Neurologia e Cardiologia de Curitiba, Curitiba, Brazil.
27 Decellularized Allografts for Pediatric Patients under 12 Years of Age with Complex Congenital Heart Disease On going study (n.100 patients) Multi-Institutional (Curitiba, São Paulo and Recife) Preliminary Results have shown excellent hemodynamics, no calcification and no reoperations up to 9 years in the Curitiba group
28 dcell Aortic Allografts 10 Years Clinical Data presented by Prof. Francisco da Costa at AATS Cardiovascular Valve Symposium November, 2015 Patients: n=103 Mean Age: Mean FU: 46± 17 (min=0,1 max=81) 4.2 years (0,1 10), 92% complete High risk patients 26 Concomitant Mitral Valve Disease (Multiple Reop) 18 Ascending Aorta / Hemiarch Aneurysm 23 Bacterial Endocarditis 6 Coronary Artery Disease 28
29 Max Gradient (mmhg Decellularized Ao Valve Allografts Late Gradients Gradient stable over time, up to 10 years Time (months)
30 Explanted Aortic Allograft 8 years of Follow-up CT Scan Evaluation Calcium Scores Aortic Wall Well preserved aortic wall Elastic fibers intact in vivo repopulation Endothelization Minimal Intimal Hyperplasia Decellularized Ao Valve Allografts Absent or Minimal Calcification on cusps and conduits up to 10 years of follow-up
31 Conclusions Decellularized Allografts have shown very promising results up to 10 years of follow-up Minimal inflammation and negligible immune reaction. They do not retract in the pulmonary circulation and do not dilate in the systemic side. Occasional biopsies have demonstrated partial repopulation of these grafts and minimal or absent calcification, even in children under the age of 12 years. This data demonstrate that decellularized allografts have, at least up to 10 years, better performance than conventional cryopreserved allografts and they are currently our graft of choice for patients at any age.
32 The future Decellularized Pulmonary Allograft with Decellularized Human Pericardium Extension Applied to Xenografts Anticalcification Method Applied to Xenografts Bovine Pericardium for Hernia Repair
33 TISSUE REGENIX GROUP P L C 33
Collagen Solutions Plc
Collagen Solutions Plc Jamal Rushdy, CEO Growth & Innovation Forum 2017 January 2017 Disclaimer This presentation is incomplete without reference to, and should be viewed solely in conjunction with the
More informationTissue Regenix. Strong prospects in wound care. Wound care market set for sustainable growth. TRX s technology well positioned in wound care
Tissue Regenix Strong prospects in wound care Wound care focus report Healthcare equipment & services Tissue Regenix s (TRX) investment case is built on dcell, a patented decellularised tissue scaffold,
More informationThe Leader in the Science of Heart Valves and Hemodynamic Monitoring
The Leader in the Science of Heart Valves and Hemodynamic Monitoring Cautionary Statement Presentations and comments made today by the management of Edwards Lifesciences Corporation will include forward
More informationAlliqua BioMedical Investor Presentation August 2017 NASDAQ: ALQA
Alliqua BioMedical Investor Presentation August 2017 NASDAQ: ALQA Forward Looking Statements Safe Harbor Statement This presentation contains forward-looking statements. Forward-looking statements are
More informationDemetrio Mauro, CFO Francesca Rambaudi, IR. London, February 22, SORIN GROUP Presentation February 22,
Demetrio Mauro, CFO Francesca Rambaudi, IR London, February 22, 2011 SORIN GROUP Presentation February 22, 2011 1 DISCLAIMER This presentation contains management preliminary estimates and forward-looking
More informationQuarterly Shareholder Update December 2017
Quarterly Shareholder Update December 2017 Dear Shareholder, Pharmaxis closed out 2017 in a good position having made significant progress in drug development with value inflection points in a number of
More informationHCT/P Regulation vs 361 Products
HCT/P Regulation - 351 vs 361 Products Presented by: Paul Gadiock February 15, 2017 Arent Fox LLP Washington, DC New York, NY Los Angeles, CA San Francisco, CA 1 Presentation Overview Introduction Public
More informationCarpentier-Edwards. ThermaFix Advanced Tissue Process. The only tissue process to remove both major calcium binding sites 5
Carpentier-Edwards ThermaFix Advanced Tissue Process The only tissue process to remove both major calcium binding sites 5 Prepare to change the way you think about tissue treatments The ThermaFix process
More informationGrupo Fleury: history, market and strategic positioning, future. Mr. Carlos Marinelli Chief Executive Officer
Grupo Fleury: history, market and strategic positioning, future Mr. Carlos Marinelli Chief Executive Officer Grupo Fleury in numbers: purpose 90 years and reference healthcare company in Brazil 145 PSCs
More informationGermany Tissue Engineered - Skin Substitutes Market Outlook to 2020
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020 Reference Code: GDMECC0884DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationProtect the Neck. Lieven Maene, MD. Marc Bosiers Koen Deloose Joren Callaert. Patrick Peeters Jürgen Verbist. Lieven Maene Roel Beelen.
A.Z. Sint-Blasius, Dendermonde Marc Bosiers Koen Deloose Joren Callaert Imelda Hospital, Bonheiden Protect the Neck Patrick Peeters Jürgen Verbist OLV Hospital, Aalst Lieven Maene Roel Beelen R.Z. Heilig
More informationPREVELEAK Surgical sealant
PREVELEAK Surgical sealant Rx only Instructions for Use DEVICE DESCRIPTION PREVELEAK Surgical sealant (PREVELEAK) is a sealant developed to seal suture holes formed during surgical repair of the circulatory
More informationMorgan Stanley - 13th Annual European Medtech Fieldtrip André-Michel Ballester, CEO. Brussels, March 8, SORIN GROUP Presentation 1
Morgan Stanley - 13th Annual European Medtech Fieldtrip André-Michel Ballester, CEO Brussels, March 8, 2011 SORIN GROUP Presentation 1 DISCLAIMER This presentation contains management preliminary estimates
More informationACCEPTED MANUSCRIPT. In situ heart valve tissue engineering: Employing the innate immune response to do the
Accepted Manuscript In situ heart valve tissue engineering: Employing the innate immune response to do the hard work F. Zafar, MD, D.L.S. Morales, MD PII: S0022-5223(18)30839-0 DOI: 10.1016/j.jtcvs.2018.03.059
More informationA Coordinated Registry Network Based on the Vascular Quality Initiative: VISION. Vascular Implant Surveillance & Interventional Outcomes Network
A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION Vascular Implant Surveillance & Interventional Outcomes Network Jack L. Cronenwett, MD Medical Director, Society for Vascular
More informationSynagis (Palivizumab)
Synagis (Palivizumab) Last Review Date: September 8, 2017 Number: MG.MM.PH.18aCv2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider
More informationTissue Products Catalogue
Tissue Products Catalogue Tissue Processing: ecoo Technology Our Tissues business segment is focused on processing tissue components such as bones, soft tissues and skin of both human and animal origin.
More informationKEY TO INNOVATION AT VASCUTEK JAPAN MATTERS FEBRUARY 7TH 2014
KEY TO INNOVATION AT VASCUTEK JAPAN MATTERS FEBRUARY 7TH 2014 VASCUTEK LTD : Background Manufacturer of synthetic vascular grafts In business since 1982 Over 500 employees Turnover around 70 million No.
More informationFor personal use only
Australia (ASX: AVH) U.S. (OTCQX: AVMXY) Galatéa de las esferas Salvador Dalí, 1952 Annual General Meeting 22 November 2013 Perth, Australia 2 This presentation may include forward looking statements.
More informationAccelerating Pre-Market Approval for Medical Devices
The National Academy of Sciences The Innovation Policy Forum Medical Devices Innovation: Opportunities, Threats, and Challenges Accelerating Pre-Market Approval for Medical Devices Michael J. Mack, MD
More informationA LEADING GLOBAL HEALTH CARE GROUP. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY
A LEADING GLOBAL HEALTH CARE GROUP Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains forward-looking statements
More informationTexas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request
Form 1033 September 2017-E Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request About Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and serious
More informationAgenda. Highlights. Q3 financials. Beta-Glucans. Enzymes. Outlook. advanced wound care. molecular testing
Agenda Highlights Q3 financials Beta-Glucans advanced wound care Enzymes molecular testing Outlook 2 Highlights International market evaluation for Woulgan Biogel by Smith & Nephew continues at several
More informationThe Active Biotech Group Interim Report January March 2001
The Active Biotech Group Interim Report January March 2001 Both key projects, SAIK-MS and TTS, are proceeding to Phase II clinical trials Increased focus on research projects in Lund Financing through
More informationSales and net income reach all-time highs 6% dividend increase proposed Positive Group outlook for 2015
Investor News February 25, 205 Birgit Grund Senior Vice President Investor Relations Fresenius SE & Co. KGaA Else-Kröner-Straße 6352 Bad Homburg Germany T +49 672 608-2485 F +49 672 608-2488 birgit.grund@fresenius.com
More informationALLODERM SELECT ALLODERM SELECT RESTORE
ALLODERM SELECT ALLODERM SELECT RESTORE Regenerative Tissue Matrix Instructions for Use Processed from donated human tissue by: LifeCell Corporation One Millennium Way Branchburg, NJ 08876-3876 DESCRIPTION
More informationBiomechanical Properties of Decellularized Porcine Pulmonary Valve Conduits
Artificial Organs ( ):, Blackwell Publishing, Inc. 2007, Copyright the Authors Journal compilation 2007, International Center for Artificial Organs and Transplantation Biomechanical Properties of Decellularized
More informationPalivizumab (Synagis ) Criteria for the Respiratory Syncytial Virus (RSV) Season for Fee-For-Service Legacy Medicaid Recipients
Palivizumab (Synagis ) Criteria for the 2017-2018 Respiratory Syncytial Virus (RSV) Season for Fee-For-Service Legacy Medicaid Recipients Palivizumab is indicated for the prevention of serious lower respiratory
More informationSirtex Medical Limited
Sirtex Medical Limited Market Update 2011 Half Year Results Gilman Wong CEO Darren Smith CFO 9-10 March 2011 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd. Understanding the Sirtex
More informationMechanical Characterization and Stimulation Solutions for Medical Device Applications
Mechanical Characterization and Stimulation Solutions for Medical Device Applications What good is an idea if it remains an idea? Try. Experiment. Iterate. Fail. Try again. Change the world. - Simon Sinek
More informationThird Quarter 2009 Results. Analysts and Media Conference November 5, 2009 Zurich
Third Quarter 2009 Results Analysts and Media Conference November 5, 2009 Zurich This presentation contains forward looking statements which involve risks and uncertainties. The actual performance, results
More informationProgress in X-Ray & MR
Progress in X-Ray & MR Michiel Manuel Analyst Meeting June 15 th, 2005 X-Ray & MR: Agenda Introduction General X-Ray Cardio/Vascular X-Ray Magnetic Resonance China growth opportunity Conclusion 2 X-Ray
More informationReplacement Heart Valve Product Description (Stented Tissue) Models Reference
Dear Imaging Center: This letter is in response to your inquiry concerning the safety of performing magnetic resonance (MR) procedures in patients who have been implanted with Edwards Lifesciences LLC
More informationMurray Sheldon, MD Associate Director for Technology and Innovation Center for Devices and Radiological Health (CDRH) Office of the Center Director
Murray Sheldon, MD Associate Director for Technology and Innovation Center for Devices and Radiological Health (CDRH) Office of the Center Director The National Academies Innovation Policy Forum September
More informationFresenius Investor News
health care worldwide August 3, 2006 Contact: Birgit Grund Fresenius AG Investor Relations Tel. ++49-6172 - 608 2485 Fax ++49-6172 - 608 2488 e-mail: ir-fre@fresenius.de Internet: www.fresenius-ag.com
More informationPhysician Office Billing & Payment Guide
Physician Office Billing & Payment Guide Dermal Regeneration Matrix Dermal Repair Scaffold Ag Antimicrobial Dermal Repair Scaffold Physician Office Billing & Payment Guide Billing and Medicare Payment
More informationReplacement Heart Valve Product Description (Stented Tissue) Models Reference
Dear Imaging Center: This letter is in response to your inquiry concerning the safety of performing magnetic resonance (MR) procedures in patients who have been implanted with Edwards Lifesciences LLC
More information2015-Tissue Storage. Welcome to the 2015 Tissue Storage survey. Please refer to the following instructions as you complete this section of the survey.
2015-Tissue Storage Form Approved OMB No. 0990-0457 Exp. Date 06/30/2020 Welcome to the 2015 Tissue Storage survey. Please refer to the following instructions as you complete this section of the survey.
More informationPHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec)
PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec) INDICATION IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable
More informationA preliminary study of prosthesis damage by laser energy. James M. Seeger, M.D., George S. Abela, M.D.,* and Nina Klingman, B.S., Gainesville, Fla.
Laser radiation in the graft stenosis treatment of prosthetic A preliminary study of prosthesis damage by laser energy James M. Seeger, M.D., George S. Abela, M.D.,* and Nina Klingman, B.S., Gainesville,
More informationStericycle, Inc. Q NASDAQ: SRCL
Stericycle, Inc. Q1 2015 NASDAQ: SRCL Forward - Looking Statements This presentation may contain forward-looking statements that involve a number of risks and uncertainties and our actual results could
More informationEvaluateMedTech has used a number of sources within the site to develop a 4-level classification tree based on the FDA approvals process.
Classification of Approvals from Devices@FDA FDA Classification EvaluateMedTech has used a number of sources within the Devices@FDA site to develop a 4-level classification tree based on the FDA approvals
More informationAcellular vascular tissues: natural biomaterials for tissue repair and tissue engineering
Biomaterials 21 (2000) 2215}2231 Acellular vascular tissues: natural biomaterials for tissue repair and tissue engineering Christine E. Schmidt*, Jennie M. Baier Department of Chemical Engineering, University
More informationThe Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes
More informationDiagnosis for Open Wounds as a Result of Cancer Resection
Diagnosis for Open Wounds as a Result of Cancer Resection December 15, 2016 What diagnosis code do we use when we are reconstructing a defect after the Moh s surgeon, or someone else removed the cancer?
More informationINTERIM RESULTS AS OF MARCH 31, 2017
INTERIM RESULTS AS OF MARCH 31, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationApril 15, 2015 VIA ELECTRONIC MAIL
April 15, 2015 VIA ELECTRONIC MAIL Patricia Brooks, RHIA Senior Technical Advisor Centers for Medicare and Medicaid Services Hospital and Ambulatory Policy Group Mail Stop C4-08-06 7500 Security Boulevard
More informationC D R H. Computational Modeling in Medical Devices. Prasanna Hariharan, PhD
Computational Modeling in Medical Devices Prasanna Hariharan, PhD Office of Science and Engineering Laboratories Division of Solid and Fluid Mechanics Prasanna.hariharan@fda.hhs.gov C D R H ASME V&V Symposium
More informationKeeping Patients and Medical Professionals at the Center of Everything We Do
Keeping Patients and Medical Professionals at the Center of Everything We Do To fulfill its corporate mission of Contributing to Society through Healthcare, Terumo continually rises to the challenge of
More informationECONOMICS OF TREATMENT CHOICE AND IMPLICATIONS FOR COST-EFFECTIVENESS POLICY. Ashley Swanson November 17, 2015
ECONOMICS OF TREATMENT CHOICE AND IMPLICATIONS FOR COST-EFFECTIVENESS POLICY Ashley Swanson November 17, 2015 What are the potential uses of CBA/CEA? Public funding of medical treatment UK (NICE) Analogous
More informationClinical Trial Outsourcing: A Case Study For Small Biotechnology Companies Operating Globally
Clinical Trial Outsourcing: A Case Study For Small Biotechnology Companies Operating Globally Cerus Corporation Concord, CA Laurence Corash, MD Chief Medical Officer Meisa Propst, Associate Director Clinical
More informationUse of Quantitative Scanning Electron Microscopy of S. aureus Biofilm Formation in vitro to Identify Strain and Implant Material Specificities
Use of Quantitative Scanning Electron Microscopy of S. aureus Biofilm Formation in vitro to Identify Strain and Implant Material Specificities Werasak Sutipornpalangkul, MD, PhD 1, Kohei Nishitani, MD,
More informationMedical Device Biocompatibility: ISO TC194 Overview & Standards
Medical Device Biocompatibility: ISO TC194 Overview & 10993 Standards Jon Cammack, PhD AstraZeneca/MedImmune R&D/Clinical Quality United States Head of Delegation (HoD), ISO TC194 Convenor, ISO TC194/WG15
More informationUnderstanding Clinical Equivalence
Understanding Clinical Equivalence BSI 2014 Medical Device Mini-Roadshow Ibim Tariah Ph.D Technical Director, Healthcare Solutions 1 Understanding Clinical Equivalence Review Requirements from Directives
More informationMechanical Engineer. If interested, please submit your resumes to
The Foundry is the premier medical device company incubator for inventors to rapidly transform their concepts into companies. The Foundry team has founded and financed ten medical device companies since
More informationHistoacryl A revolution in mesh fixation
Histoacryl A revolution in mesh fixation Closure Technologies Histoacryl A revolution in mesh fixation A new indication for a classic product Histoacryl has been used for more than 40 years in operating
More informationConference Call ITAÚSA 2010
Conference Call ITAÚSA 2010 April 04, 2011 Mário Anseloni - President & CEO 1 Financial Results R$ Million 2009 2010 2010x2009 Net Revenue 1,323 1,571 18.7% Gross Profit 270 274 1.7% Breakdown of Net Revenue
More informationInterim report January September 2017
Interim report January September 2017 Conference call, November 13 th, 2017 at 3:00 p.m. (CET) Dial-in number: SE: +46 8 566 425 08, US: +1 646 502 51 18 Peter Wolpert, CEO & Founder Anna Ljung, CFO Disclaimer
More informationMinimally Invasive Surgery
Minimally Invasive Surgery 1 RECOOP HST Research Activity Inventory Please complete the template for each selected project your organization would like to share with the partners of the RECOOP HST Consortium
More informationFrance Pressure Relief Devices Market Outlook to 2020
France Pressure Relief Devices Market Outlook to 2020 Reference Code: GDMECC0869DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More informationTRELLIS COLLAGEN RIBBON
TRELLIS COLLAGEN RIBBON 147321-1 English (en) The following languages are included in this packet: M Wright Medical Technology, Inc. 5677 Airline Rd. Arlington, TN 38002 USA www.wmt.com August 2012 Printed
More information9/29/2016. Implantable Artificial Kidney: From Silicon Chips to Renal Clearance. ESRD Statistics. Arrhythmia Care as a Paradigm
The Implantable Artificial Kidney Implantable Artificial Kidney: From Silicon Chips to Renal Clearance Shuvo Roy, PhD Professor UCSF Paul Brakeman, MD, PhD Associate Professor UCSF *Financial Disclosure
More informationHealth Reimbursement Account Preventive Care Program for Participants and Spouses
Health Reimbursement Account Preventive Care Program for Participants and Spouses EFFECTIVE DATE: JANUARY 1, 2016 The Trustees have established the Health Reimbursement Account Preventive Care Program
More informationInvestor Presentation. November 26, 2013
Investor Presentation November 26, 2013 Forward-Looking Statements This presentation may contain forward-looking statements as defined under U.S. federal securities laws. These statements reflect management's
More informationTHE AMA HANDBOOK OF DUE DILIGENCE
This is a complete list of the nearly-400 ready-to-use forms you ll find in The AMA Handbook of Due Diligence, the most exhaustive guide available on how to properly perform a due dilgence investigation
More informationASX Announcement ANNUAL GENERAL MEETING RACV CLUB LEVEL 2, 501 BOURKE ST, MELBOURNE VIC 3000 AT AM ON 28 NOVEMBER, 2017
ANNUAL GENERAL MEETING RACV CLUB LEVEL 2, 501 BOURKE ST, MELBOURNE VIC 3000 AT 11.00 AM ON 28 NOVEMBER, 2017 CHAIRMAN S ADDRESS Good morning ladies and gentlemen, I'm Roger Corbett, the Chairman of our
More informationFunctional Assessment and Clinical Outcome
Tissue Engineering Functional Assessment and Clinical Outcome STEVEN A. GOLDSTEIN Orthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan 48109,
More informationFresenius Investor News
health care worldwide October 31, 2006 Contact: Birgit Grund Fresenius AG Investor Relations Tel. ++49-6172 - 608 2485 Fax ++49-6172 - 608 2488 e-mail: ir-fre@fresenius.de Internet: www.fresenius-ag.com
More informationBRIC Surgical Sutures Market Outlook to 2020
BRIC Surgical Sutures Market Outlook to 2020 Reference Code: GDMECR0270DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...
More informationADVANCING THE ART OF SINGLE-STAGE REPAIR
ADVANCING THE ART OF SINGLE-STAGE REPAIR PREPERITONEAL PLACEMENT GORE BIO-A WEB PTFE Knit GORE BIO-A WEB OVERVIEW GORE SYNECOR Preperitoneal Biomaterial is designed specifically for preperitoneal, retromuscular
More informationFor personal use only
1047 Elwell Court, Palo Alto CA 94303 USA Tel (US): +1 (650) 390 9000 Tel (AU): 1-800-778-662 Fax: +1 650 390 9007 www.airxpanders.com ASX ANNOUNCEMENT AirXpanders issues Shareholder Newsletter PALO ALTO,
More informationUFO MOVIEZ INDIA LIMITED- IPO Note April 24, 2015
UFO MOVIEZ INDIA LIMITED- IPO te April 24, 2015 Company Overview UFO Moviez is India s largest digital cinema distribution network and in-cinema advertising platform (in terms of numbers of screens). It
More informationFinite Element Analysis of Medical Devices: WS Atkins Perspective
Industry Sector RTD Thematic Area Date Biomedical 13 th Nov 2001 Finite Element Analysis of Medical Devices: WS Atkins Perspective Stuart Kelly WS Atkins Consultants Ltd, Bristol, UK Summary: This presentation
More informationJEFFERIES HEALTHCARE CONFERENCE
JEFFERIES HEALTHCARE CONFERENCE JUNE 10, 2016 Evolution in Visual Freedom FORWARD-LOOKING STATEMENTS BUILDING A FOUNDATION FOR CONSISTENT GROWTH All statements in this presentation that are not statements
More informationLeveraging an Academic-Industry Partnership for Commercial Success
Leveraging an Academic-Industry Partnership for Commercial Success For 115 Years, the Nation s Leading Respiratory Hospital Respiratory Heritage: 115 Years of Respiratory Research and Care Allergy, Asthma,
More informationNEXT GENERATION ECM-BASED ALLOGRAFT TECHNOLOGY:
NEXT GENERATION ECM-BASED ALLOGRAFT TECHNOLOGY: Potent biological scaffolds strategically control stem cell fate and function, allowing our allografts to harness the regenerative potential of patient s
More information12 pericardial bioprostheses. 7300TFX Carpentier-Edwards bioprosthetic valved conduit
Dear Imaging Center: This letter is in response to your inquiry concerning the safety of performing magnetic resonance (MR) procedures in patients who have been implanted with Edwards Lifesciences (formerly
More informationFresenius Investor News
Analysts Meeting and Live video webcast today Fresenius Medical Care at 2.30 p.m. CET / 8.30 a.m. EDT Fresenius AG at 4.30 p.m. CET / 10.30 a.m. EDT health care worldwide May 4, 2005 Contact: Birgit Grund
More informationProducer of the ShopEasy Family of Technology Products
Shopping Solutions, Inc. (A fictitious Company) Improving the way people shop & consumer products are sold Producer of the Family of Technology Products Investor Briefing April 1 Our Leadership Team and
More informationDisclosures. Role of the Pulmonologist in a Multidisciplinary Thoracic Program. Introduction. Access. None. Access
Role of the Pulmonologist in a Multidisciplinary Thoracic Program Disclosures None Ken Y. Yoneda, M.D. Professor of Medicine Division of Pulmonary and Critical Care University of California, Davis VA Northern
More informationMedidée Services SA. Nano-Tera.ch. 05 February 2015 part 8. PMA, 510k, IDE. Pierre-Alain Sommer
Nano-Tera.ch 05 February 2015 part 8 PMA, 510k, IDE Pierre-Alain Sommer Pierre-alain.sommer@medidee.com www.medidee.com Nano-Tera 2015 05.02.2015 USA/FDA Pre Market Approval System - PMA, Pre Market Notifcation
More informationMRI Systems Market to 2018
MRI Systems Market to 2018 Technological advancements, Increasing Number of Applications and Advent of MRI Compatible Pacemakers to Drive Future Growth GBI Research Report Guidance GBI Research Report
More informationHow we deal with aortic endograft infection. Elena Iborra, Emma Espinar, Ramon Vila Hospital Universitari de Bellvitge Barcelona, Spain
How we deal with aortic endograft infection Elena Iborra, Emma Espinar, Ramon Vila Hospital Universitari de Bellvitge Barcelona, Spain Disclosure Speaker name: Elena Iborra Ortega I have the following
More informationImporting/Exporting Conventional HCT/Ps
Importing/Exporting Conventional HCT/Ps ISCT/FDA Liaison Meeting January 4, 2007 Scott A. Brubaker, CTBS American Association of Tissue Banks Conventional Tissue Banks! FDA term from the preamble to the
More informationNew creative textile construction using innovative braiding technology and materials
White Paper New creative textile construction using innovative braiding technology and materials DSM and Meister Provide Foundation for Medical Device Design Philippe Gédet, Engineer, Meister & Cie AG
More information